85 related articles for article (PubMed ID: 7772649)
1. First month of neuroleptic treatment in schizophrenia: only partial normalization of the late positive components of visual ERP.
Mintz M; Hermesh H; Glicksohn J; Munitz H; Radwan M
Biol Psychiatry; 1995 Mar; 37(6):402-9. PubMed ID: 7772649
[TBL] [Abstract][Full Text] [Related]
2. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
Asato N; Hirayasu Y; Hiramatsu K; Ohta H
Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
[TBL] [Abstract][Full Text] [Related]
3. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication.
Stefánsson SB; Jónsdóttir TJ
Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment.
Hirayasu Y; Asato N; Ohta H; Hokama H; Arakaki H; Ogura C
Biol Psychiatry; 1998 Feb; 43(4):244-53. PubMed ID: 9513733
[TBL] [Abstract][Full Text] [Related]
5. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
Nagase Y; Okubo Y; Toru M
Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
[TBL] [Abstract][Full Text] [Related]
6. The late positive component of the evoked response in acute schizophrenics during a test of sustained attention.
Pass HL; Klorman R; Salzman LF; Klein RH; Kaskey GB
Biol Psychiatry; 1980 Feb; 15(1):9-20. PubMed ID: 7357059
[TBL] [Abstract][Full Text] [Related]
7. Neuroleptic-induced lateral asymmetry of visual evoked potentials in schizophrenia.
Mintz M; Tomer R; Myslobodsky MS
Biol Psychiatry; 1982 Jul; 17(7):815-28. PubMed ID: 6126228
[TBL] [Abstract][Full Text] [Related]
8. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
[TBL] [Abstract][Full Text] [Related]
9. [The P 300 potential in schizophrenia].
Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
[TBL] [Abstract][Full Text] [Related]
10. Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
Harvey PD; Davidson M; White L; Keefe RS; Hirschowitz J; Mohs RC; Davis KL
Biol Psychiatry; 1996 Oct; 40(8):755-60. PubMed ID: 8894068
[TBL] [Abstract][Full Text] [Related]
11. Autonomic nervous system differences as predictors of short-term outcome in schizophrenics.
Straube ER; Schied HW; Rein W; Breyer-Pfaff U
Pharmacopsychiatry; 1987 May; 20(3):105-10. PubMed ID: 2885864
[TBL] [Abstract][Full Text] [Related]
12. [Selective attention and schizophrenia before the administration of neuroleptics].
Lussier I; Stip E
Encephale; 1999; 25(6):576-83. PubMed ID: 10668600
[TBL] [Abstract][Full Text] [Related]
13. Delayed peak latency of the mismatch negativity in schizophrenics and alcoholics.
Kathmann N; Wagner M; Rendtorff N; Engel RR
Biol Psychiatry; 1995 May; 37(10):754-7. PubMed ID: 7640331
[No Abstract] [Full Text] [Related]
14. Are cholinergic enhancers beneficial for memory in schizophrenia? An event-related potentials (ERPs) study of rivastigmine add-on therapy in a crossover trial.
Guillem F; Chouinard S; Poulin J; Godbout R; Lalonde P; Melun P; Bentaleb LA; Stip E
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jul; 30(5):934-45. PubMed ID: 16580765
[TBL] [Abstract][Full Text] [Related]
15. First-episode neuroleptic-free schizophrenics: concentrations of monoamines and their metabolites in plasma and their correlations with clinical responses to haloperidol treatment.
Nagaoka S; Iwamoto N; Arai H
Biol Psychiatry; 1997 Apr; 41(8):857-64. PubMed ID: 9099412
[TBL] [Abstract][Full Text] [Related]
16. ERPs in schizophrenia: effects of antipsychotic medication.
Ford JM; White PM; Csernansky JG; Faustman WO; Roth WT; Pfefferbaum A
Biol Psychiatry; 1994 Aug; 36(3):153-70. PubMed ID: 7948453
[TBL] [Abstract][Full Text] [Related]
17. [Influence of attention on an auditory-verbal learning test in schizophrenic patients].
Huguelet P; Nicastro R; Zanello A
Encephale; 2002; 28(4):291-7. PubMed ID: 12232538
[TBL] [Abstract][Full Text] [Related]
18. Influence of duration of untreated psychosis on auditory P300 in drug-naive and first-episode schizophrenia.
Wang J; Hirayasu Y; Hokama H; Tanaka S; Kondo T; Zhang M; Xiao Z
Psychiatry Clin Neurosci; 2005 Apr; 59(2):209-14. PubMed ID: 15823170
[TBL] [Abstract][Full Text] [Related]
19. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
Kopala LC; Fredrikson D; Good KP; Honer WG
Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
[No Abstract] [Full Text] [Related]
20. Impairment of recognition memory in schizophrenia: event-related potential study using a continuous recognition task.
Kim MS; Kwon JS; Kang SS; Youn T; Kang KW
Psychiatry Clin Neurosci; 2004 Oct; 58(5):465-72. PubMed ID: 15482576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
